Tillotts will acquire 100% of HPW’s interests to internalize manufacturing at that site, strengthening manufacturing capacity and quality control. The transferor is Aenova; HPW is a Germany-based site. Ownership ratio before acquisition 0% \u2192 after acquisition 100%. Execution planned for 2027 or later.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4559","jir_company_name":"Zeria Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-26","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4559-20261026-01.pdf","jir_short_summary":"Tillotts will acquire 100% of HPW's interests to internalize manufacturing at that site, strengthening manufacturing capacity and quality control. The transferor is Aenova; HPW is a Germany-based site. Ownership ratio before acquisition 0% \u2192 after acquisition 100%. Execution planned for 2027 or later.","jir_summary":"### Overview of M&A and Interest Acquisition\nZeria Pharmaceutical Co., Ltd., through its Swiss subsidiary Tillotts, will acquire all interests in Haupt Pharma W\u00fclfling GmbH held by Aenova Holding GmbH, and internalize manufacturing at that site to expand Tillotts\u2019 pharmaceutical manufacturing base. HPW possesses advanced expertise in development, manufacturing and packaging of solid dosage forms and handling of clinical trial supplies; leveraging its long-standing experience will strengthen the Group\u2019s manufacturing capacity, production planning and quality management. Closing requires approval from relevant authorities, and execution is scheduled for January 2027 or later.\n\n### Impact and Future Outlook\nThe acquisition aligns with Tillotts\u2019 long-term strategy and aims to enhance the Group\u2019s corporate value over the medium to long term. By making HPW a 100% subsidiary, expansion of manufacturing capacity and improvements in quality and production efficiency are expected, establishing a structure capable of supporting future portfolio expansion. Any additional matters requiring disclosure will be announced promptly.","jir_financial_highlights":"Net Sales: Unknown (Unknown)\nNet Assets: Unknown (Unknown)","jir_category":"","jir_hashtags":"#ShareBuyback, #BoardPersonnel, #IREarnings","jir_key_figures":"Acquired Ownership Ratio: 100%\nSchedule of Changes: Share transfer agreement signing date October 23, 2026 (Swiss time), Share transfer execution date January 2027 or later\nInvestors \/ Ownership Ratio (HPW): Aenova Holding GmbH 100%, Tillotts to make HPW a 100% subsidiary","jir_meta_title":"Zeria Pharmaceutical Co., Ltd. - Notice of Making a Subsidiary via Acquisition of Interests | October 2026","jir_meta_description":"Zeria Pharmaceutical Co., Ltd. announces that Tillotts will acquire all interests in Haupt Pharma W\u00fclfling GmbH and internalize manufacturing at the site. Details on the transferor, schedule and impact are provided.","jir_og_title":"Zeria Pharmaceutical Co., Ltd. - Notice of Making a Subsidiary via Acquisition of Interests","jir_og_description":"Strategic acquisition in which Tillotts will acquire 100% of HPW to internalize manufacturing. Agreement signing date 2026\/10\/23; execution planned for 2027 or later.","jir_og_image_url":"\/assets\/og\/company-m_and_a_alliance.jpg","jir_chart_data_collection":"[]","ir_related_company":9548,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"m_and_a_alliance","footnotes":""},"sector":[],"importance":[],"class_list":["post-134083","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n